Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential [Yahoo! Finance]
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
SRPT Stock Surges on Promising Early Results From siRNA Programs [Yahoo! Finance]
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead [Seeking Alpha]
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets [Yahoo! Finance]